| Literature DB >> 27738874 |
Adrià Dangla-Valls1, José Luis Molinuevo2,3, Jordi Altirriba4, Raquel Sánchez-Valle1, Daniel Alcolea5,6, Juan Fortea5,6, Lorena Rami1, Mircea Balasa1, Cristina Muñoz-García1, Mario Ezquerra7, Rubén Fernández-Santiago7, Alberto Lleó5,6, Albert Lladó1, Anna Antonell1.
Abstract
MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression through post-transcriptional repression of target genes. They have been shown to be implicated in the pathophysiology of Alzheimer's disease (AD) and proposed as disease biomarkers. In the present work, we have studied the expression levels of 754 miRNAs in cerebrospinal fluid (CSF) from AD patients and control subjects. We have explored a first screening cohort (N = 20) and selected 12 miRNAs to be further tested in a second independent validation cohort (N = 69). We have found a significant upregulation of miR-222 and miR-125b in AD CSF. Of these, the association of miR-222 with AD is novel and reported here for the first time whereas upregulation of miR-125b has been previously reported in AD brain. Yet we do not find association with other miRNAs which were previously linked to AD. Our results shed light on potential underlying pathophysiological processes of AD and also point out the need for consensus procedures in CSF miRNA detection and data analysis.Entities:
Keywords: Alzheimer’s disease; Biomarkers; Cerebrospinal fluid; miR-125b; miR-222; microRNAs
Mesh:
Substances:
Year: 2016 PMID: 27738874 DOI: 10.1007/s12035-016-0106-x
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590